Literature DB >> 27821590

Heparan Sulfate and Heparin Promote Faithful Prion Replication in Vitro by Binding to Normal and Abnormal Prion Proteins in Protein Misfolding Cyclic Amplification.

Morikazu Imamura1, Naoko Tabeta2, Nobuko Kato2, Yuichi Matsuura2, Yoshifumi Iwamaru2, Takashi Yokoyama2, Yuichi Murayama2.   

Abstract

The precise mechanism underlying the conversion of normal prion protein (PrPC) into abnormal prion protein (PrPSc) remains unclear. Protein misfolding cyclic amplification (PMCA), an in vitro technique used for amplifying PrPSc, results in PrPSc replication that preserves the strain-specific characteristics of the input PrPSc; thus, PMCA mimics the process of in vivo PrPSc replication. Previous work has demonstrated that in PMCA, nucleic acids are critical for PrPSc amplification, but little information has been reported on glycosaminoglycan (GAG) participation in PrPSc replication in vitro Here, we investigated whether GAGs play a role in the faithful replication of PrPSc by using a modified PMCA performed with baculovirus-derived recombinant PrP (Bac-PrP) as a substrate. The addition of heparan sulfate (HS) or its analog heparin (HP) restored the conversion efficiency in PMCA that was inhibited through nucleic acid depletion. Moreover, the PMCA products obtained under these conditions were infectious and preserved the properties of the input PrPSc These data suggest that HS and HP play the same role as nucleic acids in facilitating faithful replication of prions in PMCA. Furthermore, we showed that HP binds to both Bac-PrP and Bac-PrPSc through the sulfated groups present on HP and that the N-terminal domain of Bac-PrPSc might potentially not be involved in the binding to HP. These results suggest that the interaction of GAGs such as HS and HP with PrPC and/or PrPSc through their sulfate groups is critical for the faithful replication of prions.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  baculovirus-recombinant prion protein; heparan sulfate; heparin; prion; prion disease; protein folding; protein misfolding cyclic amplification

Mesh:

Substances:

Year:  2016        PMID: 27821590      PMCID: PMC5159508          DOI: 10.1074/jbc.M116.745851

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  57 in total

1.  Structural changes of the prion protein in lipid membranes leading to aggregation and fibrillization.

Authors:  Jurate Kazlauskaite; Narinder Sanghera; Ian Sylvester; Catherine Vénien-Bryan; Teresa J T Pinheiro
Journal:  Biochemistry       Date:  2003-03-25       Impact factor: 3.162

2.  Heparin enhances the cell-protein misfolding cyclic amplification efficiency of variant Creutzfeldt-Jakob disease.

Authors:  Takashi Yokoyama; Atsuko Takeuchi; Miyuki Yamamoto; Tetsuyuki Kitamoto; James W Ironside; Masanori Morita
Journal:  Neurosci Lett       Date:  2011-05-05       Impact factor: 3.046

3.  Generating a prion with bacterially expressed recombinant prion protein.

Authors:  Fei Wang; Xinhe Wang; Chong-Gang Yuan; Jiyan Ma
Journal:  Science       Date:  2010-01-28       Impact factor: 47.728

4.  Glycosaminoglycan sulfation determines the biochemical properties of prion protein aggregates.

Authors:  Laura J Ellett; Bradley M Coleman; Mitch C Shambrook; Vanessa A Johanssen; Steven J Collins; Colin L Masters; Andrew F Hill; Victoria A Lawson
Journal:  Glycobiology       Date:  2015-02-20       Impact factor: 4.313

5.  Binding of bovine prion protein to heparin: a fluorescence polarization study.

Authors:  Olga Andrievskaia; Zhanna Potetinova; Aru Balachandran; Klaus Nielsen
Journal:  Arch Biochem Biophys       Date:  2007-02-23       Impact factor: 4.013

Review 6.  Prion diseases of humans and animals: their causes and molecular basis.

Authors:  J Collinge
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

7.  Urinary excretion and blood level of prions in scrapie-infected hamsters.

Authors:  Yuichi Murayama; Miyako Yoshioka; Hiroyuki Okada; Masuhiro Takata; Takashi Yokoyama; Shirou Mohri
Journal:  J Gen Virol       Date:  2007-10       Impact factor: 3.891

8.  Polyanion induced fibril growth enables the development of a reproducible assay in solution for the screening of fibril interfering compounds, and the investigation of the prion nucleation site.

Authors:  Ronald S Boshuizen; Michela Morbin; Giulia Mazzoleni; Fabrizio Tagliavini; Rob H Meloen; Johannes P M Langedijk
Journal:  Amyloid       Date:  2007-09       Impact factor: 7.141

9.  De novo generation of infectious prions with bacterially expressed recombinant prion protein.

Authors:  Zhihong Zhang; Yi Zhang; Fei Wang; Xinhe Wang; Yuanyuan Xu; Huaiyi Yang; Guohua Yu; Chonggang Yuan; Jiyan Ma
Journal:  FASEB J       Date:  2013-08-22       Impact factor: 5.191

10.  Insect cell-derived cofactors become fully functional after proteinase K and heat treatment for high-fidelity amplification of glycosylphosphatidylinositol-anchored recombinant scrapie and BSE prion proteins.

Authors:  Morikazu Imamura; Nobuko Kato; Hiroyuki Okada; Miyako Yoshioka; Yoshifumi Iwamaru; Yoshihisa Shimizu; Shirou Mohri; Takashi Yokoyama; Yuichi Murayama
Journal:  PLoS One       Date:  2013-12-18       Impact factor: 3.240

View more
  13 in total

1.  Prion protein glycans reduce intracerebral fibril formation and spongiosis in prion disease.

Authors:  Alejandro M Sevillano; Patricia Aguilar-Calvo; Timothy D Kurt; Jessica A Lawrence; Katrin Soldau; Thu H Nam; Taylor Schumann; Donald P Pizzo; Sofie Nyström; Biswa Choudhury; Hermann Altmeppen; Jeffrey D Esko; Markus Glatzel; K Peter R Nilsson; Christina J Sigurdson
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

2.  Correlation of cellular factors and differential scrapie prion permissiveness in ovine microglia.

Authors:  Kelcey D Dinkel; David A Schneider; Juan F Muñoz-Gutiérrez; Valerie R McElliott; James B Stanton
Journal:  Virus Res       Date:  2017-07-25       Impact factor: 3.303

3.  Comparative analysis of heparin affecting the biochemical properties of chicken and murine prion proteins.

Authors:  Li-Juan Wang; Xiao-Dan Gu; Xiao-Xiao Li; Liang Shen; Hong-Fang Ji
Journal:  PLoS One       Date:  2021-02-18       Impact factor: 3.240

Review 4.  Therapeutic development of polymers for prion disease.

Authors:  Kenta Teruya; Katsumi Doh-Ura
Journal:  Cell Tissue Res       Date:  2022-03-21       Impact factor: 5.249

Review 5.  Extracellular vesicles with diagnostic and therapeutic potential for prion diseases.

Authors:  Arun Khadka; Jereme G Spiers; Lesley Cheng; Andrew F Hill
Journal:  Cell Tissue Res       Date:  2022-04-08       Impact factor: 5.249

6.  Transcriptomic analysis identifies novel potential biomarkers and highlights cilium-related biological processes in the early stages of prion disease in mice.

Authors:  Yong-Chan Kim; Byung-Hoon Jeong
Journal:  Prion       Date:  2022-12       Impact factor: 2.547

Review 7.  Cell biology of prion strains in vivo and in vitro.

Authors:  Daniel Shoup; Suzette A Priola
Journal:  Cell Tissue Res       Date:  2022-02-02       Impact factor: 5.249

8.  Rapid amplification of prions from variant Creutzfeldt-Jakob disease cerebrospinal fluid.

Authors:  Marcelo A Barria; Andrew Lee; Alison Je Green; Richard Knight; Mark W Head
Journal:  J Pathol Clin Res       Date:  2018-02-05

Review 9.  Understanding Prion Strains: Evidence from Studies of the Disease Forms Affecting Humans.

Authors:  Marcello Rossi; Simone Baiardi; Piero Parchi
Journal:  Viruses       Date:  2019-03-29       Impact factor: 5.048

10.  Shortening heparan sulfate chains prolongs survival and reduces parenchymal plaques in prion disease caused by mobile, ADAM10-cleaved prions.

Authors:  Patricia Aguilar-Calvo; Alejandro M Sevillano; Jaidev Bapat; Katrin Soldau; Daniel R Sandoval; Hermann C Altmeppen; Luise Linsenmeier; Donald P Pizzo; Michael D Geschwind; Henry Sanchez; Brian S Appleby; Mark L Cohen; Jiri G Safar; Steven D Edland; Markus Glatzel; K Peter R Nilsson; Jeffrey D Esko; Christina J Sigurdson
Journal:  Acta Neuropathol       Date:  2019-10-31       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.